1. Market Research
  2. > Healthcare Market Trends
  3. > Healthcare Analysis & Statistics 2020 - United Kingdom

Healthcare Analysis & Statistics 2020 - United Kingdom

Customer Support

Talk to Ahmad

+1 718 618 4302

Publishers

  • All
    • Pharma Intelligence

All regions

1-17 of 17 reports

Non-Small Cell Lung Cancer (NSCLC) KOL Interview – UK

  • $ 599
  • March 2020
  • 12 pages

This interview with a UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for non-small cell lung cancer (NSCLC). Diagnostic ...

  • Cancer
  • Lung Cancer
  • Pathology
  • United Kingdom
  • Market Size

HER2+ Breast Cancer KOL Interview – UK

  • $ 599
  • March 2020
  • 17 pages

A UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for HER2+ breast cancer. Diagnostic testing, biomarker disease segmentation, ...

  • Breast Cancer
  • United Kingdom
  • Market Size

Type 1 Diabetes KOL Interview – UK

  • $ 599
  • January 2020
  • 13 pages

This interview with a UK Key Opinion Leader (KOL) provides insight into current therapies for type 1 diabetes, as well as pricing pressures within the diabetes market, the unmet needs in type 1 diabetes, ...

  • Chronic Disease
  • Diabetes
  • Type 1 Diabetes
  • United Kingdom
  • Market Size

Triple-Negative Breast Cancer KOL Interview – UK

  • $ 599
  • October 2019
  • 15 pages

A UK-based key opinion leader providers insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for triple- negative breast cancer. Diagnostic testing, biomarker disease ...

  • Breast Cancer
  • Targeted Therapy
  • Therapy
  • United Kingdom
  • Market Size

Rheumatoid Arthritis Payer Interview – UK

  • $ 599
  • August 2019
  • 18 pages

Overview A UK payer provides insights into pricing and reimbursement dynamics and issues surrounding biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis.

  • Arthritis
  • Chronic Disease
  • Medical Biotechnology
  • United Kingdom
  • Market Size

Rheumatoid Arthritis KOL Interview – UK

  • $ 599
  • July 2019
  • 14 pages

A UK-based key opinion leader provides insights into prescribing habits, the most pressing unmet needs in the market, the role of biosimilars, key marketed brands, and late-phase pipeline therapies fo ...

  • Arthritis
  • Biosimilar
  • Medical Biotechnology
  • United Kingdom
  • Market Size

Latuda

  • $ 10000
  • March 2019
  • 39 pages

Latuda (lurasidone; Sumitomo Dainippon/Angelini) contains the atypical antipsychotic lurasidone, which acts as an antagonist of dopamine receptors D2, and serotonin receptors 5-HT2A. By inhibiting the ...

  • Healthcare
  • Mental Health
  • Pathology
  • Psychotic Disorder
  • United Kingdom

Datamonitor Healthcare Hepatocellular Carcinoma (HCC) KOL Interview – UK

  • $ 599
  • February 2019
  • 13 pages

Overview This interview covers hepatocellular carcinoma (HCC) treatment trends in the UK. We discuss current options for first- and second-line treatment, as well as therapies that are currently in Phase ...

  • Healthcare
  • Hepatitis
  • Pathology
  • United Kingdom
  • Product Initiative

Alzheimer’s Disease KOL Interview – UK

  • $ 599
  • January 2019
  • 14 pages

Overview This interview with a UK key opinion leader (KOL) provides an overview of cost-effectiveness criteria that may be required to bring Alzheimer’s disease products successfully to the clinic in ...

  • Dementia
  • Mental Health
  • Pathology
  • United Kingdom

Datamonitor Healthcare Multiple Myeloma KOL Interview – Midwestern, US

  • $ 599
  • January 2019
  • 17 pages

Overview This interview covers the current treatment of multiple myeloma in the UK, and the main areas of unmet need. Looking forward, we discuss the likely uptake of recently approved regimens, as well ...

  • Cancer
  • Healthcare
  • United Kingdom
  • United States

Datamonitor Healthcare Multiple Myeloma KOL Interview – UK

  • $ 599
  • January 2019
  • 17 pages

Overview This interview covers the current treatment of multiple myeloma in the UK, and the main areas of unmet need. Looking forward, we discuss the likely uptake of recently approved regimens, as well ...

  • Cancer
  • Healthcare
  • United Kingdom

Datamonitor Healthcare HR+/HER2- Breast Cancer KOL Interview – UK

  • $ 599
  • January 2019
  • 14 pages

Overview A UK key opinion leader (KOL) provides insight into the current and future treatment dynamics of HR+/HER2- breast cancer, as well as critical unmet needs in the treatment space. Major marketed ...

  • Breast Cancer
  • Cancer
  • Healthcare
  • Pathology
  • United Kingdom

Major Depressive Disorder KOL Interview – UK

  • $ 599
  • December 2018
  • 11 pages

Overview A UK key opinion leader (KOL) provides insight into the critical unmet needs in the depression market, along with future trends. Key late-phase pipeline drugs for major depressive disorder and ...

  • Depression
  • Mental Health
  • United Kingdom
  • Forecast
  • Market Size

Datamonitor Healthcare Seasonal Influenza Vaccines KOL Interview – UK

  • $ 599
  • November 2018
  • 14 pages

Overview An interview with a UK key opinion leader (KOL) on seasonal influenza vaccination coverage rates and trends in main risk groups, key marketed vaccines, pipeline approaches, and the potential fo ...

  • Healthcare
  • Influenza
  • Vaccine
  • United Kingdom
  • Social Conditions

Datamonitor Healthcare Meningococcal and Pneumococcal Vaccines KOL Interview – UK

  • $ 599
  • November 2018
  • 13 pages

Overview An interview with a UK key opinion leader (KOL) on meningococcal and pneumococcal vaccination coverage rates, vaccination rate trends in main risk groups, key marketed vaccines, pipeline approaches, ...

  • Healthcare
  • Vaccine
  • United Kingdom
  • Market Size
  • Social Conditions

Datamonitor Healthcare Type 2 Diabetes KOL Interview – UK

  • $ 599
  • October 2018
  • 11 pages

Overview In this discussion with a UK KOL, we cover topics related to the shift in market dynamics in recent years and what goes into the decision-making process when prescribing antidiabetics for patients. ...

  • Antidiabetics
  • Healthcare
  • Type 2 Diabetes
  • United Kingdom
  • Forecast

Bronchitol

  • $ 10000
  • September 2018
  • 17 pages

Drug Overview Bronchitol is an inhaled dry powder formulation of mannitol, a naturally occurring monosaccharide that also acts as a mucolytic agent. Once inhaled, Bronchitol has an osmotic effect that ...

  • Cystic Fibrosis
  • Healthcare
  • Pathology
  • United Kingdom
  • Demand


About 12000 reports

Download Unlimited Documents from Trusted Public Sources

View report >

Pathology Statistics in the UK

  • July 2020
  • 28 pages
  • Healthcare
  • Pathology
  • United Kingdom
  • Demographic

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on